Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2009-03-19 M&A Activity
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
M&A Activity Classification · 98% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations). The core content explicitly states: 'Attached hereto is a report on An asset Purchase Agreement with Bio Gal Ltd.' and references an attached PDF file related to this agreement. This indicates the document itself is an announcement about a significant corporate action (an asset purchase agreement), not the agreement document itself, nor a standard periodic report like 10-K or IR. Since the transaction involves a merger/acquisition/takeover proposal or agreement, the most fitting category is 'M&A Activity' (TAR). It is not a general regulatory filing (RNS) because a more specific category exists, and it is not a Report Publication Announcement (RPA) because it announces the substance of the transaction, not just the publication of a previously known report.
2009-03-19 English
Immediate Report
Board/Management Information Classification · 95% confidence The document is an announcement of the results of Extraordinary General Meetings (EGMs) held by XTL Biopharmaceuticals Ltd. It details the passing of resolutions, changes in the board of directors, appointments of external directors, resignations of former board members, and management changes including CEO and finance officer departures. It also mentions shareholder approval for corporate actions such as reverse split and share capital increase. The document is not a full report but a communication of meeting outcomes and management changes. Therefore, it fits best under Board/Management Information (MANG) as it primarily announces changes in the company's board and senior management following the EGMs. The document length is 3366 characters, which is relatively short and consistent with an announcement rather than a full report. Confidence is high due to clear references to board and management changes and shareholder meeting results.
2009-03-18 Hebrew (modern)
Immediate Report
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations). The key content states: 'Attached hereto is a report on *the results of the Company's Extraordinary General Meetings (�EGMs�) held earlier today.*' and lists a PDF file named 'EGM_March_2009_StatementFinal_isa.pdf'. This explicitly indicates the document is an announcement about the results of a shareholder vote from a general meeting (EGM). This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). It is not the full AGM presentation (AGM-R) or a proxy solicitation (PSI), but the results announcement.
2009-03-18 English
Board/Management Information 2009
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports the results of Extraordinary General Meetings (EGMs), including board and management changes, appointment of new directors, resignations, and management updates. The document also mentions shareholder approval for corporate actions like reverse split and ADR ratio changes. The content focuses on board and management changes and shareholder meeting results rather than financial statements or earnings. The document length is 5541 characters, which is sufficient to contain substantive information rather than just an announcement. Therefore, the document fits best under Board/Management Information (MANG) because it announces changes in the company's board of directors and senior management following the EGMs. It also includes some voting results, but the primary focus is on management changes rather than just voting results, so MANG is more appropriate than DVA.
2009-03-18 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It announces the postponement of Extraordinary General Meetings (EGMs) due to lack of quorum and provides details about the rescheduled meetings. The document is relatively short (3222 characters) and primarily serves as an announcement regarding shareholder meetings rather than containing detailed financial data or full reports. It does not contain financial statements or detailed management discussion. The content focuses on meeting scheduling and proxy voting information, which aligns with announcements related to shareholder meetings but not the voting results themselves. Therefore, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2009-03-11 English
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is a short announcement about the postponement of Extraordinary General Meetings (EGMs) due to lack of quorum, specifying the new date and voting procedures. It does not contain any financial data, detailed meeting materials, or voting results. It is an announcement related to shareholder meetings but not the meeting materials or voting results themselves. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2009-03-11 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.